Molecular target drug development for curing multiple sclerosis

Brain and Nerve

Volumn 61, Issue 8, 2009, Pages 923-928

  Yamamura, Takashi ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

Clinical trial; Humanized antibody; Integrin; Multiple sclerosis (MS); Sphingosine I phosphate (SIP)

Indexed keywords

ABATACEPT; ALEMTUZUMAB; ALPHA4 INTEGRIN; ATACICEPT; BAF 312; CD20 ANTIGEN; CD52 ANTIGEN; CDP 323; CS 0777; DACLIZUMAB; FINGOLIMOD; FIRATEGRAST; GLATIRAMER; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 23; LY 2127399; NATALIZUMAB; NEUROMUSCULAR DEPOLARIZING AGENT; OFATUMUMAB; RG 2077; RITUXIMAB; RTL 1000; UNCLASSIFIED DRUG; USTEKINUMAB; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 1;

DRUG DEVELOPMENT; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; HUMAN; IMMUNE SYSTEM; JC VIRUS; MULTIPLE SCLEROSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; VIRUS INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNITY; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; INTEGRIN ALPHA4BETA1; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LIGANDS; LYSOPHOSPHOLIPIDS; MULTIPLE SCLEROSIS; OPPORTUNISTIC INFECTIONS; PROPYLENE GLYCOLS; RECEPTORS, ANTIGEN, T-CELL; SPHINGOSINE;

EID: 69549086582     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, et al: Axonal transaction in the lesions of multiple sclerosis. N Engl J Med 338: 278-285, 1998 (Pubitemid 28065253)
2. Sospedra M, Martin R: Immunology of multiple sclerosis. Ann Rev Immunol 23: 683-747, 2005
3. Croxford JL, Yamamura T: Back to the future for multiple sclerosis therapy. Focus on current and emerging disease-modifying strategies. Immunotherapy 1: 403-423, 2009
4. Neuhaus O, Farina C, Wekerle H, Hohlfeld R: Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56: 702-708, 2001 (Pubitemid 32240087)
5. Niino M, Bodner C, Simard ML, Alatab S, Gano D, et al: Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 59: 748-754, 2006 (Pubitemid 43673152)
6. Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC: Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 71: 766-773, 2008
7. Offner H, Sinha S, Wang C, Burrows GG, Vandenbark AA: Recombinant T-cell receptor ligands: Immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis. Rev Neurosci 19: 327-339, 2008
8. Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, et al: CTLA4Ig treatment in patients with multiple sclerosis. An open-label, phase 1 clinical trial. Neurology 71: 917-924, 2008
9. Bielekova B, Howard T, Packer AN, Richert N, Blevins G, et al: Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 66: 483-489, 2009
10. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, et al: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355: 1124-1140, 2006 (Pubitemid 44394919)
11. CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, et al: Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N Engl J Med 359: 1786 - 1801, 2008
12. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, et al: Repeated subcutaneous injections of IL12/IL23 p40 neutralizing antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomized, dose-ranging study. Lancet Neurol 7: 796-804, 2008
13. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, et al: B-cell depletion with rituximab in relapsing-reitting multiple sclerosis. N Engl J Med 358: 676-688, 2008 (Pubitemid 351240747)
14. Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, et al: Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63: 395-400, 2008 (Pubitemid 351240747)
15. Mi S, Hu B, Hahm K, Luo Y, Kam Hui ES, et al: LINGO-1 antagonis promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 13: 1228-1233, 2007 (Pubitemid 47530642)
16. Garren H, Robinson WH, Krasulová E, Havrdová E, Nadj C, et 1: Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 63: 611-620, 2008
17. Williams RO, Feldmann M, Maini RN: Anti-tumor necrosis factorameliorates joint disease in murine collagen-induced arthritis. PNAS 89: 9784-9788, 1992
18. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, et al: Prevention of experimental autoimmune encephalomyelitis by antibodies against α;4β2 integrin. Nature 356: 63-66, 1992
19. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, et al: Encephalitogenic potential of the myelin basic protein peptide (aino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with and altered peptide ligand. Nat Med 6: 1167-1175, 2000 (Pubitemid 30792198)
20. Kremer JM, Genant HK, Moreland LW, Russell A, Emery P, et al: Effects of Abatacet in patients with methotrexate-esistant active rheumatoid arthritis. A randomized trial. Ann Int Med 144: 865-876, 2006 (Pubitemid 46768126)
21. Huxkey-Jones J, Foord SM, Barnes MR: Drug discovery in the extracellular matrix. Drug Discorvery Today 13: 685-694, 2008
22. Davenport R, Munday J: Blocking α4-integrins - A small molecule approach to treatment of multiple sclerosis. J Neurol Sci 274: 27-30, 2008
23. Khatri BO, Man S, Giovannoni G, Koo AP, Lee JC, et al: Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72: 402-409, 2009
24. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, et al: Regulatory CD56 bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. PNAS 103: 5941-5946, 2006
25. Adachi K, Chiba K: FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosohate receptor agonists as immunomodulators based on reverse pharmacology. Perspectives Med Chem 1: 11-23, 2007
26. O'Connor P, Comi G, Montalban X, Antel J, Radue EW, et al: Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 72: 73-79, 2009
27. Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, et al: FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 71: 1261-1267, 2008
28. Kivisäkk P, Healy BC, Viglietta V, Quintana FJ, Hootstein MA, et al: Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 72: 1922-1930, 2009